Sturgeon Catharine M, Ellis Andrew R
Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, United Kingdom.
Clin Chim Acta. 2007 May;381(1):85-92. doi: 10.1016/j.cca.2007.02.015. Epub 2007 Feb 20.
Commutability of immunoassay test results is an important objective for laboratory medicine.
PSA is a clinically important analyte for which, as a consequence of a number of national and international initiatives over the last decade, considerable progress has been made towards improving method comparability. However, results from different assays are still not interchangeable, a situation that is only likely to improve once broad recommendations can be made about the most clinically relevant antibody combinations.
Universal implementation of such recommendations would almost certainly improve between-method agreement substantially, provided careful attention were paid to assay design and use of appropriately pure secondary standards ensured.
免疫分析检测结果的互换性是检验医学的一个重要目标。
前列腺特异性抗原(PSA)是一种具有临床重要性的分析物,由于过去十年的一些国家和国际倡议,在提高方法可比性方面已取得了相当大的进展。然而,不同检测方法的结果仍不可互换,只有在能够就最具临床相关性的抗体组合提出广泛建议后,这种情况才可能得到改善。
如果对检测设计给予仔细关注并确保使用适当纯度的二级标准品,那么这些建议的普遍实施几乎肯定会大幅提高方法间的一致性。